

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias	TM151	TM152	TM153	TM154	TM155	Average bias	
CA125 all lab mean:							CA125 TOSOH AIA (TOM/TO1) mean:						
mean	≤ 5.0	23.1	36.3	41.8	49.0		mean	≤ 2.0	24.1	39.1	45.0	54.5	
SD		3.4	5.0	6.1	7.2		SD		2.7	1.4	3.8	4.1	
%CV		14.6%	13.7%	14.6%	14.7%		%CV		11.1%	3.7%	8.5%	7.6%	
N	40	118	117	119	118		mean+3SD		32.2	43.4	56.4	66.9	
mean+3SD	4.2	33.3	51.2	60.0	70.6		mean-3SD		16.1	34.7	33.5	42.1	
mean-3SD		13.0	21.4	23.5	27.4		N		5	5	5	5	
mean/all kit median		1.00	1.01	0.98	1.00	1.00	kit median		23.9	39.2	46.3	55.5	
							mean/all kit median		1.04	1.09	1.06	1.11	1.07
CA125 TOSOH ST-AIA (TOM/TO2) mean:							CA125 Immulite & Immulite 1000 (DPB/DP5) mean:						
mean	< 2.0	29.4	43.3	50.4	62.7		mean	< 2.0	23.0	36.0	42.5	49.0	
N		2	2	2	2		SD		2.4	2.1	3.9	6.1	
mean/all kit median		1.26	1.20	1.19	1.27	1.23	%CV		10.5%	5.9%	9.1%	12.4%	
							mean+3SD		30.3	42.3	54.1	67.2	
							mean-3SD		15.7	29.7	30.9	30.8	
							N		4	4	4	4	
							kit median		22.6	35.8	42.5	49.4	
							mean/all kit median		0.99	1.00	1.00	1.00	1.00
CA125 Abbott Asxym & Imx (ABB & ABM/AB1) mean:							CA125 Immulite 2000 (DPD/DP5) mean:						
mean	≤ 6.0	27.6	45.2	50.4	59.2		mean	≤ 5.0	23.2	35.4	42.1	49.2	
SD		3.5	4.1	6.7	5.3		SD		1.4	2.5	2.0	3.0	
%CV		12.6%	9.1%	13.3%	9.0%		%CV		6.1%	7.0%	4.8%	6.0%	
mean+3SD		38.1	57.7	70.5	75.2		mean+3SD		27.5	42.8	48.1	58.1	
mean-3SD		17.2	32.8	30.2	43.2		mean-3SD		19.0	27.9	36.0	40.3	
N		19	19	19	19		N		29	29	29	29	
kit median		27.4	45.3	50.4	58.1		kit median		23.6	35.8	42.4	50.1	
mean/all kit median		1.19	1.26	1.19	1.20	1.21	mean/all kit median		1.00	0.98	0.99	1.00	0.99
CA125 Beckman Unicel & Access (BCU & BCX/BC1) mean:							CA125 Bayer ADVIDA Centaur (COB/BA1) mean:						
mean	≤ 2.0	26.0	40.0	47.9	56.7		mean	≤ 5.0	23.2	35.4	40.7	46.9	
SD		1.0	1.3	2.3	1.9		SD		1.1	1.9	2.9	3.0	
%CV		3.7%	3.2%	4.8%	3.3%		%CV		4.6%	5.3%	7.1%	6.3%	
mean+3SD		28.9	43.8	54.9	62.3		mean+3SD		26.4	41.0	49.4	55.8	
mean-3SD		23.1	36.2	41.0	51.1		mean-3SD		20.0	29.8	32.0	38.0	
N		7	7	7	7		N		27	28	29	29	
kit median		25.9	40.3	49.0	56.9		kit median		23.0	35.9	40.9	47.0	
mean/all kit median		1.12	1.11	1.13	1.15	1.13	mean/all kit median		1.00	0.98	0.96	0.95	0.97

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
CA125 Elecsys 1010/2010 & E170 (BME & BMR/BM1) mean:							CA125 Johnson & Johnson Vitros (JJC/JJ1) mean:						
mean	≤ 5.0	19.4	30.7	33.8	39.5		mean	≤ 2.0	17.6	29.1	34.0	40.1	
SD		1.4	1.6	2.0	3.2		SD		1.3	2.3	2.4	2.4	
%CV		7.1%	5.3%	5.9%	8.1%		%CV		7.3%	7.9%	7.1%	5.9%	
mean+3SD		23.5	35.6	39.7	49.1		mean+3SD		21.4	36.0	41.3	47.2	
mean-3SD		15.3	25.8	27.8	29.9		mean-3SD		13.7	22.2	26.7	33.0	
N		16	16	16	16		N		7	7	7	7	
kit median		19.7	30.6	33.6	39.8		kit median		17.1	28.7	34.0	40.0	
mean/all kit median		0.83	0.85	0.79	0.80	0.82	mean/all kit median		0.76	0.81	0.80	0.81	0.79
							CA125 kit average:						
							mean	< 6.0	23.7	37.1	43.0	50.9	
							SD		3.7	5.3	6.2	8.1	
							all kit median		23.2	36.0	42.5	49.2	

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
CA27.29 all lab mean:							CA27.29 Bayer ADVIA-Centaur (COB/BA1) mean:						
mean	< 15	23.7	61.6	38.3	50.6		mean	< 15	23.1	61.4	37.9	50.5	
SD		3.8	3.9	4.1	3.8		SD		3.5	3.8	4.1	3.2	
%CV		16.0%	6.3%	10.7%	7.6%		%CV		15.0%	6.1%	10.8%	6.3%	
mean+3SD	2.7	35.1	73.3	50.6	62.1		mean+3SD		33.5	72.7	50.2	60.1	
mean-3SD		12.4	50.0	26.1	39.0		mean-3SD		12.7	50.1	25.7	41.0	
N	10	52	52	52	51		N		43	43	43	42	
kit median							kit median		22.9	61.7	38.4	50.6	
mean/all kit median		0.93	0.99	1.00	0.99	0.98	mean/all kit median		0.90	0.99	0.99	0.99	0.97
CA27.29 TOSOH ST-AIA (TOM/TO2) mean:							CA27.29 Bayer ACS-180 (COS/BA1) mean:						
mean	≤ 3	30.6	64.9	43.4	54.9		mean	≤ 4	23.2	63.1	39.0	51.7	
SD		3.9	5.2	4.3	5.9		SD		0.6	4.6	2.8	3.6	
%CV		12.8%	8.0%	9.9%	10.8%		%CV		2.5%	7.3%	7.3%	6.9%	
mean+3SD		42.3	80.6	56.2	72.7		mean+3SD		24.9	76.8	47.5	62.5	
mean-3SD		18.9	49.3	30.6	37.1		mean-3SD		21.4	49.3	30.5	41.0	
N		3	3	3	3		N		4	4	4	3	
kit median		30.7	67.0	44.8	54.2		kit median		23.2	64.6	38.9	53.8	
mean/all kit median		1.20	1.04	1.13	1.07	1.11	mean/all kit median		0.91	1.01	1.01	1.01	0.99
CA27.29 TOSOH AIA (TOM/TO1) mean:							CA27.29 kit average:						
mean	< 3	28.0	58.8	37.8	49.0		mean	< 15	26.2	62.0	39.5	51.5	
N		2	2	2	2		SD		3.7	2.6	2.6	2.5	
mean/all kit median		1.09	0.94	0.98	0.96	0.99	all kit median		25.6	62.2	38.5	51.1	

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
CA15-3 all lab mean:							CA15-3 Johnson & Johnson (JJC/JJ1) mean:						
mean	≤15	32.10	70.83	46.04	59.53		mean	≤ 8	24.5	56.8	35.7	46.4	
SD		9.11	20.25	12.80	17.78		SD		2.0	5.5	3.4	4.1	
%CV		28.4%	28.6%	27.8%	29.9%		%CV		8.3%	9.7%	9.4%	8.9%	
N	12	49	49	49	49		N	3	3	3	3	3	
mean+3SD	1.6	59.4	131.6	84.4	112.9		mean+3SD		30.7	73.4	45.8	58.7	
mean-3SD		4.8	10.1	7.7	6.2		mean-3SD		18.4	40.3	25.6	34.0	
mean/all kit median		1.21	1.21	1.19	1.21	1.20	kit median		25.4	55.1	35.8	47.2	
							mean/all kit median		0.92	0.97	0.93	0.94	0.94
CA15-3 DPC Immulite 1000/2000 (DPB & DPD/DP5) mean:							CA15-3 Roche Elecsys (BME & BMR/BM1) mean:						
mean	≤ 1.0	47.9	105.9	68.3	90.7		mean	≤ 2.0	25.0	55.0	36.3	45.1	
SD		2.3	3.4	2.8	4.4		SD		1.2	2.8	1.4	1.7	
%CV		4.8%	3.2%	4.2%	4.9%		%CV		4.8%	5.1%	4.0%	3.7%	
N		11	11	11	11		N		5	5	5	5	
mean+3SD		54.9	116.2	76.8	104.0		mean+3SD		28.6	63.4	40.6	50.2	
mean-3SD		41.0	95.7	59.8	77.4		mean-3SD		21.4	46.6	32.0	40.1	
kit median		47.6	105.0	68.6	91.2		kit median		25.4	54.2	35.7	45.7	
mean/all kit median		1.80	1.81	1.77	1.84	1.81	mean/all kit median		0.94	0.94	0.94	0.92	0.93
CA15-3 Bayer ADVIA-Centaur (COB/BA1) mean:							CA15-3 Beckman Unicel & Access (BCU & BCX/BC1) mean:						
mean	< 2.0	29.7	65.9	42.6	54.4		mean	< 1.0	24.0	52.5	34.2	43.8	
SD		1.9	5.1	2.9	4.0		SD		0.9	1.2	0.7	0.6	
%CV		6.4%	7.8%	6.9%	7.4%		%CV		3.6%	2.3%	2.1%	1.3%	
N		17	17	17	17		N		3	3	3	3	
mean+3SD		35.4	81.3	51.5	66.5		mean+3SD		26.6	56.2	36.3	45.5	
mean-3SD		23.9	50.5	33.8	42.4		mean-3SD		21.4	48.8	32.0	42.2	
kit median		30.0	66.4	42.0	54.5		kit median		23.8	52.0	34.3	44.1	
mean/all kit median		1.11	1.12	1.11	1.11	1.11	mean/all kit median		0.90	0.90	0.89	0.89	0.89
CA15-3 Abbott Asxym (ABB/AB1) mean:							CA15-3 kit average:						
mean	≤15	28.3	60.5	40.7	52.0		mean	≤15	29.9	66.1	43.0	55.4	
SD		2.7	8.0	3.8	3.5		SD		9.1	20.1	12.8	17.8	
%CV		9.5%	13.2%	9.4%	6.8%		all kit median		26.6	58.7	38.5	49.2	
N		8	8	8	8								
mean+3SD		36.3	84.4	52.3	62.6								
mean-3SD		20.2	36.5	29.2	41.4								
kit median		29.0	61.5	40.4	52.4								
mean/all kit median		1.06	1.03	1.06	1.06	1.05							

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
CA19-9 all lab mean:							CA19-9 DPC Immulite (DPD/DP5) mean:						
mean	≤ 7.0	28.7	51.1	61.4	41.1		mean	≤ 3.0	22.4	42.2	47.4	31.5	
SD		6.2	9.5	13.4	8.6		SD		1.2	4.0	5.2	2.5	
%CV		21.8%	18.7%	21.8%	20.9%		%CV		5.3%	9.4%	10.9%	7.9%	
N	16	53	53	53	53		N	4	4	4	4	4	
mean+3SD	2.2	47.5	79.8	101.6	66.8		mean+3SD		26.0	54.1	62.9	39.0	
mean-3SD		10.0	22.5	21.2	15.3		mean-3SD		18.8	30.2	32.0	24.0	
mean/all kit median		1.28	1.21	1.30	1.30	1.27	kit median		22.2	40.6	46.1	31.9	
							mean/all kit median		1.00	1.00	1.00	1.00	1.00
CA19-9 Fujirebio/Centocor (GAA/CE1) mean:							CA19-9 Roche Elecsys & E170 (BME & BMR/BM1) mean:						
mean	< 7.0	36.8	61.6	74.3	51.2		mean	< 3.0	20.9	38.7	45.9	30.7	
N		2	2	2	2		SD		0.8	1.5	2.5	1.8	
mean/all kit median		1.64	1.46	1.57	1.62	1.57	%CV		4.0%	4.0%	5.5%	6.0%	
							N		5	5	5	5	
CA19-9 Bayer ADVIA-Centaur (COB/BA1) mean:							CA19-9 TOSOH A1A (TOM/TO1) mean:						
mean	≤ 3.0	33.2	58.2	71.5	47.6		mean	≤ 3.0	19.9	38.0	39.0	30.4	
SD		2.7	4.0	4.5	2.8		N		2	2	2	2	
%CV		8.0%	6.8%	6.2%	5.9%		mean/all kit median		0.89	0.90	0.82	0.97	0.89
N		29	29	29	29		CA19-9 TOSOH ST-A1A (TOM/TO2) mean:						
mean+3SD		41.2	70.1	84.8	56.1		mean	≤ 3.0	17.4	33.8	33.1	26.9	
mean-3SD		25.2	46.3	58.1	39.2		N		2	2	2	2	
kit median		33.0	58.0	71.8	48.0		mean/all kit median		0.77	0.80	0.70	0.85	0.78
mean/all kit median		1.48	1.38	1.51	1.51	1.47	CA19-9 kit average:						
							mean	< 7.0	24.9	45.2	51.9	35.9	
CA19-9 Beckman Unicel & Access (BCU & BCX/BC1) mean:							SD		7.3	10.6	15.6	9.4	
mean	≤ 3.0	24.0	43.8	52.4	33.2		all kit median		22.4	42.2	47.4	31.5	
SD		1.6	2.4	2.7	1.9								
%CV		6.6%	5.5%	5.2%	5.7%								
N		9	9	9	9								
mean+3SD		28.7	51.0	60.6	38.9								
mean-3SD		19.3	36.6	44.3	27.5								
kit median		23.4	42.3	51.5	32.6								
mean/all kit median		1.07	1.04	1.11	1.05	1.07							

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
CEA all lab mean:							CEA Bayer ACS-180 (COS/BA1) mean:						
mean	1.7	5.6	16.6	20.2	20.1		mean	2.0	5.8	18.3	21.3	21.7	
SD	0.3	0.6	2.0	2.5	2.6		SD	0.1	0.5	1.1	1.9	0.4	
%CV	16.7%	10.7%	11.9%	12.4%	13.2%		%CV	6.6%	8.3%	5.7%	8.7%	2.0%	
mean+3SD	2.5	7.4	22.6	27.7	28.0		mean+3SD	2.3	7.2	21.5	26.9	23.0	
mean-3SD	0.8	3.8	10.7	12.7	12.2		mean-3SD	1.6	4.3	15.2	15.7	20.3	
N	180	180	179	181	181		N	4	4	4	4	4	
mean/all kit median	1.02	0.98	1.02	0.98	0.99	1.00	kit median	2.0	5.8	18.5	20.9	21.6	
							mean/all kit median	1.19	1.01	1.12	1.03	1.07	1.08
CEA TOSOH ST-AIA (TOM/TO2) mean:							CEA Bayer ADVIA-Centaur (COB/BA1) mean:						
mean	2.4	8.4	23.8	29.3	28.9		mean	1.9	5.9	17.7	21.1	21.2	
N	2	2	2	2	2		SD	0.2	0.4	1.0	1.2	1.5	
mean/all kit median	1.43	1.47	1.45	1.42	1.42	1.44	%CV	11.5%	6.2%	5.8%	5.9%	7.1%	
							mean+3SD	2.6	7.0	20.8	24.8	25.7	
							mean-3SD	1.3	4.8	14.6	17.4	16.8	
							N	56	57	58	58	58	
							kit median	1.9	5.9	17.8	21.0	21.3	
							mean/all kit median	1.17	1.03	1.08	1.02	1.05	1.07
CEA TOSOH AIA (TOM/TO1) mean:							CEA DPC Immulite/1000 (DPB/DP5) mean:						
mean	1.8	6.9	19.7	23.8	23.7		mean	1.5	5.8	18.8	23.0	23.4	
SD	0.1	0.2	0.3	0.7	0.6		SD	0.2	0.1	0.5	0.5	0.1	
%CV	4.7%	2.6%	1.6%	3.1%	2.4%		%CV	12.4%	1.6%	2.5%	2.1%	0.4%	
mean+3SD	2.0	7.5	20.7	26.0	25.4		mean+3SD	2.1	6.1	20.2	24.4	23.7	
mean-3SD	1.5	6.4	18.8	21.5	22.0		mean-3SD	1.0	5.5	17.4	21.5	23.1	
N	5	5	5	5	5		N	4	4	4	4	4	
kit median	1.8	6.9	19.9	23.4	23.6		kit median	1.5	5.9	19.0	23.0	23.5	
mean/all kit median	1.08	1.21	1.21	1.15	1.17	1.16	mean/all kit median	0.93	1.02	1.15	1.11	1.16	1.07
CEA DPC Immulite 2000 (DPD/DP5) mean:							CEA Abbott IMx (ABM/AB1) mean:						
mean	1.6	6.3	19.6	24.0	24.1		mean	1.7	5.8	16.4	20.6	20.7	
SD	0.1	0.5	1.3	1.6	1.5		SD	0.1	0.3	0.3	0.5	0.4	
%CV	8.5%	7.7%	6.7%	6.7%	6.3%		%CV	5.9%	5.3%	2.0%	2.2%	1.7%	
mean+3SD	2.1	7.7	23.6	28.8	28.6		mean+3SD	2.0	6.7	17.4	22.0	21.8	
mean-3SD	1.2	4.8	15.6	19.2	19.5		mean-3SD	1.4	4.9	15.5	19.2	19.6	
N	15	15	15	15	15		N	3	3	3	3	3	
kit median	1.6	6.4	19.3	24.3	23.5		kit median	1.7	5.7	16.3	20.5	20.8	
mean/all kit median	1.00	1.10	1.20	1.16	1.19	1.13	mean/all kit median	1.03	1.01	1.00	1.00	1.02	1.01

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
CEA Abbott Asxym (ABB/AB1) mean:							CEA Beckman Unicel (BCU/BC1) mean:						
mean	1.7	5.7	16.3	20.7	19.8		mean	1.5	5.0	15.0	17.9	17.6	
SD	0.2	0.3	1.1	1.1	1.4		SD	0.1	0.3	0.9	0.6	0.6	
%CV	9.9%	5.1%	6.5%	5.4%	7.0%		%CV	7.3%	5.9%	6.0%	3.2%	3.4%	
mean+3SD	2.2	6.5	19.5	24.1	24.0		mean+3SD	1.8	5.9	17.8	19.6	19.4	
mean-3SD	1.2	4.8	13.2	17.4	15.7		mean-3SD	1.1	4.1	12.3	16.2	15.8	
N	25	24	25	24	25		N	12	12	12	12	12	
kit median	1.8	5.7	16.4	20.8	19.8		kit median	1.5	5.0	15.0	17.8	17.6	
mean/all kit median	1.04	0.99	1.00	1.00	0.98	1.00	mean/all kit median	0.89	0.88	0.92	0.87	0.87	0.88
CEA Johnson & Johnson Vitros Eci (JJC/JJ1) mean:							CEA Roche Elecsys 1010/2010 (BME/BM1) mean:						
mean	1.3	5.3	15.8	19.5	18.8		mean	1.4	4.8	13.4	16.4	16.1	
SD	0.3	0.4	0.7	0.7	0.9		SD	0.1	0.3	0.5	0.9	0.7	
%CV	22.0%	6.9%	4.2%	3.7%	5.0%		%CV	8.1%	5.2%	4.1%	5.4%	4.3%	
mean+3SD	2.2	6.4	17.7	21.6	21.6		mean+3SD	1.8	5.5	15.0	19.0	18.2	
mean-3SD	0.4	4.2	13.8	17.3	16.0		mean-3SD	1.1	4.0	11.8	13.7	14.0	
N	12	12	12	12	12		N	13	13	13	13	13	
kit median	1.3	5.4	15.8	19.6	18.8		kit median	1.4	4.8	13.5	16.3	15.9	
mean/all kit median	0.79	0.92	0.96	0.94	0.93	0.91	mean/all kit median	0.86	0.84	0.82	0.79	0.79	0.82
CEA Beckman Access (BCX/BC1) mean:							CEA Bayer ADVIA-IMS (COM/BA1) mean:						
mean	1.5	5.1	14.9	17.7	17.7		mean	1.4	4.9	13.8	16.0	16.1	
SD	0.1	0.3	0.8	0.8	0.9		SD	0.4	0.5	1.1	1.3	0.9	
%CV	7.8%	6.4%	5.4%	4.6%	4.8%		N	2	2	2	2	2	
mean+3SD	1.8	6.1	17.3	20.1	20.3		mean/all kit median	0.85	0.85	0.84	0.77	0.79	0.82
mean-3SD	1.1	4.1	12.5	15.2	15.2								
N	16	16	16	16	16								
kit median	1.5	5.1	14.9	18.0	17.9								
mean/all kit median	0.89	0.89	0.91	0.86	0.87	0.89							
CEA Roche Elecsys E170 (BMR/BM1) mean:							CEA kit average:						
mean	1.6	5.2	14.2	17.3	17.1		mean	1.7	5.8	17.0	20.6	20.5	
SD	0.2	0.3	0.4	0.5	0.5		SD	0.3	1.0	2.9	3.6	3.7	
%CV	9.2%	5.9%	2.7%	2.9%	3.0%		all kit median	1.6	5.7	16.4	20.7	20.3	
mean+3SD	2.1	6.1	15.4	18.8	18.6								
mean-3SD	1.2	4.2	13.1	15.8	15.5								
N	9	9	9	9	9								
kit median	1.6	5.0	14.2	17.3	16.9								
mean/all kit median	1.00	0.90	0.87	0.84	0.84	0.89							

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
AFP all lab mean:							AFP Bayer ADVIDA Centaur (COB/BA1) mean:						
mean	7.1	10.5	16.6	22.8	33.2		mean	8.1	10.7	16.2	22.1	31.8	
SD	0.7	0.9	1.4	2.0	2.8		SD	1.1	0.8	1.1	1.0	1.3	
%CV	10.0%	8.1%	8.5%	8.6%	8.4%		%CV	13.1%	7.1%	6.7%	4.4%	4.1%	
mean+3SD	9.2	13.1	20.8	28.7	41.6		mean+3SD	11.3	13.0	19.4	25.1	35.7	
mean-3SD	5.0	8.0	12.4	16.9	24.8		mean-3SD	4.9	8.4	13.0	19.2	27.9	
N	99	102	99	101	100		N	24	24	23	24	23	
mean/target	1.18	1.17	1.12	1.10	1.10	1.13	kit median	8.0	10.7	16.2	22.5	31.8	
							mean/target	1.35	1.19	1.09	1.07	1.05	1.15
AFP Beckman Access (BCX/BC1) mean:							AFP Abbott Asxym (ABB/AB1) mean:						
mean	7.3	11.0	18.0	24.9	35.9		mean	6.8	10.2	16.2	23.9	33.3	
SD	0.4	0.6	1.0	1.1	1.6		SD	0.5	0.8	1.9	3.1	3.8	
%CV	5.8%	5.5%	5.3%	4.5%	4.5%		%CV	7.6%	8.1%	11.6%	12.9%	11.4%	
mean+3SD	8.5	12.7	20.9	28.2	40.8		mean+3SD	8.3	12.7	21.8	33.1	44.7	
mean-3SD	6.0	9.2	15.1	21.6	31.0		mean-3SD	5.2	7.7	10.5	14.7	21.9	
N	4	4	4	4	4		N	16	16	16	16	16	
kit median	7.1	11.1	17.8	24.8	36.6		kit median	6.9	10.5	16.7	24.2	34.6	
mean/target	1.21	1.22	1.21	1.20	1.19	1.21	mean/target	1.13	1.14	1.09	1.16	1.10	1.12
AFP Beckman Unicel (BCU/BC1) mean:							AFP Roche Elecsys 1010/2010 (BME/BM1) mean:						
mean	7.1	11.3	18.0	24.4	35.5		mean	6.7	10.3	16.6	23.0	33.5	
SD	0.8	1.2	1.8	3.0	3.0		SD	0.5	0.4	1.2	1.2	1.6	
%CV	11.0%	10.7%	10.1%	12.4%	8.4%		%CV	6.9%	3.7%	7.5%	5.2%	4.9%	
mean+3SD	9.5	14.9	23.4	33.5	44.4		mean+3SD	8.1	11.4	20.4	26.6	38.3	
mean-3SD	4.8	7.7	12.5	15.3	26.6		mean-3SD	5.3	9.2	12.9	19.4	28.6	
N	9	9	9	9	9		N	5	5	5	5	5	
kit median	7.1	11.7	18.2	25.0	35.0		kit median	6.6	10.2	15.8	22.5	32.7	
mean/target	1.19	1.25	1.21	1.18	1.18	1.20	mean/target	1.12	1.14	1.12	1.11	1.11	1.12
AFP Roche E170 (BMR/BM1) mean:							AFP Immulite 2000 (DPD/DP5) mean:						
mean	7.0	10.8	17.7	24.6	36.0		mean	6.8	10.5	16.5	22.3	32.8	
SD	0.3	0.5	0.5	0.5	1.0		SD	0.4	0.5	0.9	1.2	1.5	
%CV	3.8%	5.0%	3.1%	1.9%	2.7%		%CV	5.7%	5.0%	5.2%	5.4%	4.4%	
mean+3SD	7.7	12.5	19.3	25.9	38.9		mean+3SD	8.0	12.0	19.1	25.9	37.2	
mean-3SD	6.2	9.2	16.0	23.2	33.1		mean-3SD	5.7	8.9	13.9	18.7	28.4	
N	8	8	8	8	8		N	23	23	22	23	23	
kit median	6.9	10.6	17.8	24.4	36.0		kit median	6.9	10.5	16.7	22.4	33.0	
mean/target	1.16	1.20	1.19	1.19	1.19	1.19	mean/target	1.14	1.16	1.11	1.08	1.09	1.12
AFP TOSOH ST-A1A (TOM/TO2) mean:							AFP Bayer ACS 180 (COS/BA1) mean:						
mean	7.1	11.0	17.7	24.2	35.4		mean	7.7	9.9	16.1	21.2	30.8	
N	2	2	2	2	2		N	2	2	2	2	2	
mean/target	1.18	1.22	1.18	1.17	1.17	1.18	mean/target	1.28	1.09	1.08	1.02	1.02	1.10

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155		TM151	TM152	TM153	TM154	TM155		
AFP Immulite & Immulite 1000 (DPB/DP5) mean:							AFP Johnson & Johnson Vitros Eci (JJC/JJ1) mean:						
mean	6.6	10.1	16.2	22.4	31.0		mean	7.0	9.3	13.6	18.4	26.5	
SD	0.7	1.2	1.9	2.8	6.4		SD	0.2	0.2	0.5	0.7	1.2	
%CV	10.6%	11.7%	11.8%	12.3%	20.7%		%CV	2.2%	2.2%	3.9%	3.9%	4.5%	
mean+3SD	8.7	13.6	21.9	30.7	50.2		mean+3SD	7.4	9.9	15.2	20.6	30.0	
mean-3SD	4.5	6.6	10.4	14.1	11.8		mean-3SD	6.5	8.6	12.0	16.2	22.9	
N	3	3	3	3	3		N	3	3	3	3	3	
kit median	6.3	9.8	15.6	21.2	27.5		kit median	7.0	9.2	13.8	18.2	26.1	
mean/target	1.10	1.12	1.09	1.08	1.03	1.08	mean/target	1.16	1.03	0.91	0.89	0.88	0.97
AFP TOSOH A1A (TOM/TO1) mean:							AFP	TM151	TM152	TM153	TM154	TM155	
mean	6.4	10.1	16.4	22.0	32.9		*IS target	6.0	9.0	14.9	20.7	30.2	
N	2	2	2	2	2		SD (+/-)	0.1	0.6	1.0	1.4	1.9	
mean/target	1.07	1.12	1.10	1.06	1.09	1.09	% CV	2.1	6.9	6.8	6.7	6.2	
							high (30%)	7.8	11.7	19.4	26.9	39.3	
							low (30%)	4.2	6.3	10.4	14.5	21.1	
AFP kit average:							* target value from a traceable AFP standard						
mean	7.0	10.4	16.6	22.8	32.9								
SD	0.5	0.6	1.2	1.8	2.7								
all kit median	7.0	10.4	16.5	22.7	33.1								

	TM151	TM152	TM153	TM154	TM155	Average bias	TM151	TM152	TM153	TM154	TM155	Average bias	
PSA all lab mean:							PSA Beckman Access (BCX/BC1) mean:						
mean	2.4	3.8	6.5	11.3	18.7		mean	2.6	4.1	7.2	12.4	20.7	
SD	0.2	0.3	0.6	1.0	1.7		SD	0.1	0.2	0.3	0.6	0.9	
%CV	9.8%	9.1%	8.9%	8.5%	9.1%		%CV	5.7%	4.7%	4.5%	4.5%	4.6%	
mean+3SD	3.1	4.8	8.3	14.2	23.7		mean+3SD	3.0	4.7	8.2	14.0	23.6	
mean-3SD	1.7	2.7	4.8	8.4	13.6		mean-3SD	2.1	3.5	6.2	10.7	17.9	
N	273	275	275	272	273		N	41	42	42	40	41	
kit median	2.9	4.4	7.3	12.3	20.2		kit median	2.6	4.1	7.2	12.4	20.6	
mean/target	1.04	1.07	1.09	1.05	1.05	1.06	mean/target	1.12	1.17	1.20	1.15	1.17	1.16
PSA Johnson & Johnson Vitros Eci (JJC/JJ1) mean:							PSA TOSOH AIA (TOM/TO1) mean:						
mean	2.9	4.4	7.3	12.3	20.2		mean	2.6	4.0	7.0	12.2	20.3	
SD	0.1	0.2	0.4	0.6	1.0		SD	0.2	0.3	0.4	1.0	1.6	
%CV	4.2%	4.3%	4.9%	4.7%	5.1%		%CV	8.1%	6.8%	6.2%	7.8%	7.9%	
mean+3SD	3.3	4.9	8.3	14.1	23.3		mean+3SD	3.2	4.8	8.3	15.1	25.1	
mean-3SD	2.6	3.8	6.2	10.6	17.1		mean-3SD	2.0	3.2	5.7	9.4	15.5	
N	13	13	13	13	13		N	12	12	12	12	12	
kit median	2.9	4.4	7.3	12.3	20.2		kit median	2.7	4.1	7.0	12.2	20.7	
mean/target	1.27	1.25	1.21	1.15	1.14	1.21	mean/target	1.13	1.15	1.17	1.14	1.15	1.15

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
PSA Beckman Unicel (BCU/BC1) mean:							PSA Abbott Asxym Mono/mono (ABB/AB2) mean:						
mean	2.5	4.0	7.1	12.1	19.8		mean	2.4	3.8	6.5	11.3	19.2	
SD	0.1	0.2	0.3	0.4	0.9		SD	0.2	0.3	0.4	0.8	1.2	
%CV	5.0%	4.9%	3.6%	3.5%	4.4%		%CV	8.4%	7.2%	6.4%	6.7%	6.3%	
mean+3SD	2.9	4.6	7.8	13.4	22.4		mean+3SD	3.0	4.6	7.8	13.6	22.8	
mean-3SD	2.1	3.4	6.3	10.9	17.1		mean-3SD	1.8	2.9	5.3	9.1	15.6	
N	15	15	15	15	15		N	19	19	19	18	18	
kit median	2.5	4.0	7.2	12.0	20.0		kit median	2.4	3.7	6.5	11.2	19.2	
mean/target	1.10	1.15	1.18	1.13	1.12	1.14	mean/target	1.05	1.07	1.09	1.06	1.08	1.07
PSA Bayer ACS180 (COS/BA2) mean:							PSA TOSOH ST-AIA (TOM/TO2) mean:						
mean	2.7	4.1	6.5	11.4	19.1		mean	2.4	3.8	6.6	11.6	18.8	
SD	0.1	0.1	0.4	0.2	0.7		N	2	2	2	2	2	
%CV	4.3%	2.1%	6.1%	2.1%	3.9%		mean/target	1.04	1.09	1.10	1.08	1.06	1.07
mean+3SD	3.0	4.3	7.6	12.1	21.3		PSA Abbott IMX Mono/mono (ABM/AB2) mean:						
mean-3SD	2.3	3.8	5.3	10.7	16.8		mean	2.5	3.8	6.5	11.6	18.7	
N	5	5	5	5	5		N	2	2	2	2	2	
kit median	2.7	4.1	6.4	11.3	19.1	1.11	mean/target	1.07	1.07	1.08	1.08	1.05	1.07
mean/target	1.16	1.17	1.08	1.07	1.08		PSA Dade Behring Dimension (DUD/DA1) mean:						
PSA Abbott Architect Mono/mono (ABH/AB2) mean:							mean	2.4	3.7	6.5	11.4	19.0	
mean	2.4	3.9	6.9	12.0	20.1		SD	0.2	0.2	0.3	0.5	0.8	
N	2	2	2	2	2		%CV	6.9%	5.3%	5.0%	4.6%	4.1%	
mean/target	1.04	1.11	1.15	1.12	1.14	1.11	mean+3SD	2.9	4.2	7.5	13.0	21.3	
PSA Bayer ADVIA-IMS (COM/BA2) mean:							mean-3SD	1.9	3.1	5.5	9.9	16.6	
mean	2.5	3.8	6.8	11.7	19.3		N	25	24	25	25	25	
N	2	2	2	2	2		kit median	2.4	3.6	6.5	11.4	19.0	
mean/target	1.09	1.07	1.13	1.09	1.09	1.09	mean/target	1.04	1.05	1.08	1.07	1.07	1.06
PSA Abbott Asxym (ABB/AB1) mean:							PSA Roche E170 (BMR/BM1) mean:						
mean	2.5	3.7	6.7	11.4	19.0		mean	2.3	3.6	6.2	10.7	17.6	
SD	0.2	0.2	0.4	0.4	1.2		SD	0.1	0.2	0.3	0.4	0.7	
%CV	6.7%	5.4%	6.7%	3.6%	6.5%		%CV	6.3%	4.4%	4.0%	3.7%	3.9%	
mean+3SD	2.9	4.3	8.0	12.6	22.7		mean+3SD	2.7	4.1	7.0	11.8	19.7	
mean-3SD	2.0	3.1	5.3	10.2	15.3		mean-3SD	1.8	3.1	5.5	9.5	15.6	
N	11	11	11	11	11		N	13	13	13	13	13	
kit median	2.5	3.7	6.6	11.3	19.4		kit median	2.3	3.6	6.2	10.5	17.7	
mean/target	1.07	1.06	1.11	1.06	1.07	1.08	mean/target	0.99	1.03	1.04	1.00	1.00	1.01

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155	Average bias		TM151	TM152	TM153	TM154	TM155	Average bias
PSA DPC Immulite & 1000 (DPB/DP5) mean:							PSA DPC Immulite 1000 & 2000 3G (DPB & DPD/DP6) mean:						
mean	2.2	3.6	6.3	10.7	17.3		mean	2.2	3.6	6.3	10.9	16.2	
SD	0.1	0.2	0.3	0.5	0.9		SD	0.2	0.3	0.6	0.7	1.0	
%CV	5.9%	5.3%	4.7%	4.6%	5.4%		%CV	9.6%	8.3%	9.6%	6.5%	6.4%	
mean+3SD	2.6	4.2	7.2	12.2	20.2		mean+3SD	2.8	4.5	8.2	13.0	19.4	
mean-3SD	1.8	3.0	5.4	9.3	14.5		mean-3SD	1.5	2.7	4.5	8.7	13.1	
N	14	14	14	14	14		N	3	3	3	3	3	
kit median	2.2	3.6	6.3	10.9	17.4		kit median	2.1	3.6	6.2	11.0	15.9	
mean/target	0.97	1.02	1.05	1.00	0.98	1.00	mean/target	0.94	1.03	1.06	1.02	0.92	0.99

PSA Bayer ADVIA-Centaur (COB/BA2) mean:							PSA Roche Elecsys (BME/BM1) mean:						
mean	2.3	3.5	6.0	10.5	17.4		mean	2.2	3.4	5.9	10.1	16.6	
SD	0.2	0.2	0.3	0.6	1.0		SD	0.1	0.1	0.2	0.3	0.6	
%CV	7.0%	4.7%	5.3%	5.7%	5.8%		%CV	6.4%	3.9%	3.3%	3.3%	3.5%	
mean+3SD	2.7	4.0	7.0	12.3	20.5		mean+3SD	2.6	3.8	6.5	11.1	18.4	
mean-3SD	1.8	3.0	5.1	8.7	14.4		mean-3SD	1.8	3.0	5.3	9.1	14.9	
N	53	53	53	53	53		N	18	18	18	18	18	
kit median	2.3	3.5	6.0	10.5	17.3		kit median	2.2	3.4	6.0	10.2	16.7	
mean/target	0.99	1.00	1.01	0.98	0.98	0.99	mean/target	0.96	0.97	0.99	0.95	0.94	0.96

PSA DPC Immulite 2000 (DPD/DP5) mean:						PSA					
	TM151	TM152	TM153	TM154	TM155		TM151	TM152	TM153	TM154	TM155
mean	2.2	3.5	6.0	10.8	17.3	* Assigned IS target	2.3	3.5	6.0	10.7	17.7
SD	0.2	0.3	0.4	0.6	0.9	SD (+/-)	0.1	0.1	0.2	0.6	0.7
%CV	9.2%	7.7%	7.0%	5.7%	5.0%	% CV	4.2%	3.5%	3.9%	5.2%	4.0%
mean+3SD	2.8	4.3	7.3	12.6	19.8	high (25%)			7.5	13.4	22.1
mean-3SD	1.6	2.7	4.8	8.9	14.7	low (25%)			4.5	8.0	13.3
N	18	18	18	18	18	high (30%)	3	4.6			
kit median	2.2	3.5	6.2	10.8	17.1	low (30%)	1.6	2.5			
mean/target	0.95	0.99	1.00	1.01	0.97	0.99	* target value from a traceable PSA standard				

PSA kit average:							
	TM151	TM152	TM153	TM154	TM155	mean	SD
mean	2.4	3.8	6.6	11.4	18.7	Average Bias all labs	1.070
SD	0.2	0.3	0.4	0.7	1.3	Average Bias Low Group (N=12)	1.033
all kit median	2.4	3.8	6.5	11.4	19.0	Average Bias High Group (N=6)	1.145
							0.069
							0.046
							0.036

New York State Proficiency Test May 2006

Summary of Results

	TM151	TM152	TM153	TM154	TM155		TM151	TM152	TM153	TM154	TM155		
free PSA all lab mean:							free PSA Dade Behring Dimension (DUD/DA1) mean:						
mean	0.27	0.41	0.71	1.19	1.90		mean	0.23	0.36	0.58	1.00	1.62	
SD	0.08	0.09	0.15	0.22	0.33		SD	0.05	0.03	0.04	0.08	0.06	
%CV	27.5%	21.9%	21.5%	18.0%	17.4%		%CV	20.1%	8.1%	6.4%	7.8%	3.8%	
mean+3SD	0.50	0.68	1.16	1.84	2.89		mean+3SD	0.36	0.45	0.69	1.23	1.81	
mean-3SD	0.05	0.14	0.25	0.55	0.90		mean-3SD	0.09	0.28	0.47	0.76	1.44	
N	61	65	70	63	62		N	4	5	5	4	4	
mean/target	1.14	1.20	1.39	1.18	1.19	1.22	kit median	0.23	0.36	0.58	0.97	1.64	
							mean/target	0.95	1.07	1.14	0.99	1.02	1.03
free PSA Beckman Access (BCX/BC1) mean:							free PSA Roche Elecsys (BME/BM2) mean:						
mean	0.33	0.47	0.85	1.38	2.24		mean	0.23	0.32	0.58	1.01	1.67	
SD	0.06	0.06	0.08	0.10	0.09		SD	0.04	0.04	0.05	0.08	0.08	
%CV	19.1%	11.8%	9.3%	7.4%	4.0%		%CV	18.1%	14.1%	7.9%	8.4%	4.7%	
mean+3SD	0.51	0.64	1.08	1.69	2.51		mean+3SD	0.36	0.45	0.72	1.26	1.91	
mean-3SD	0.14	0.30	0.61	1.08	1.97		mean-3SD	0.11	0.18	0.44	0.76	1.44	
N	20	23	24	20	19		N	7	7	8	8	7	
kit median	0.31	0.45	0.85	1.35	2.24		kit median	0.26	0.29	0.60	1.01	1.63	
mean/target	1.36	1.38	1.66	1.37	1.41	1.44	mean/target	0.98	0.93	1.14	1.00	1.05	1.02
free PSA Beckman Unicel (BCU/BC1) mean:							free PSA Abbott Asxym (ABB/AB2) mean:						
mean	0.31	0.49	0.83	1.39	2.09		mean	0.23	0.31	0.53	0.92	1.61	
SD	0.07	0.05	0.07	0.09	0.30		SD	0.05	0.03	0.01	0.10	0.10	
%CV	22.7%	9.2%	8.4%	6.3%	14.3%		%CV	23.9%	11.2%	2.8%	11.2%	6.3%	
mean+3SD	0.52	0.63	1.04	1.65	2.99		mean+3SD	0.39	0.41	0.57	1.22	1.91	
mean-3SD	0.10	0.36	0.62	1.13	1.19		mean-3SD	0.06	0.20	0.48	0.61	1.30	
N	12	12	12	12	12		N	4	4	5	4	4	
kit median	0.29	0.50	0.83	1.41	2.21		kit median	0.25	0.31	0.53	0.92	1.60	
mean/target	1.30	1.45	1.63	1.38	1.32	1.41	mean/target	0.95	0.90	1.04	0.91	1.01	0.96
free PSA Roche E170 (BMR/BM2) mean:							free PSA DPC Immulite 2000 (DPD/DP5) mean:						
mean	0.23	0.35	0.59	1.04	1.65		mean	0.19	0.29	0.54	0.93	1.53	
SD	0.05	0.04	0.05	0.07	0.12		SD	0.05	0.03	0.05	0.06	0.14	
%CV	20.6%	11.6%	8.0%	6.4%	7.0%		%CV	24.9%	9.1%	9.9%	6.9%	9.3%	
mean+3SD	0.37	0.48	0.73	1.24	2.00		mean+3SD	0.34	0.37	0.69	1.13	1.95	
mean-3SD	0.09	0.23	0.45	0.84	1.31		mean-3SD	0.05	0.21	0.38	0.74	1.11	
N	8	8	10	9	9		N	4	4	4	4	4	
kit median	0.21	0.36	0.57	1.03	1.60		kit median	0.21	0.30	0.54	0.93	1.54	
mean/target	0.94	1.04	1.16	1.03	1.04	1.04	mean/target	0.80	0.85	1.05	0.92	0.96	0.92
free PSA kit average:							free PSA	TM151	TM152	TM153	TM154	TM155	
mean	0.25	0.37	0.64	1.10	1.77		* IS target	0.24	0.34	0.51	1.01	1.59	
SD	0.05	0.08	0.14	0.20	0.27		SD (+/-)	0.01	0.01	0.01	0.03	0.08	
all kit median	0.23	0.35	0.58	1.01	1.65		% CV	2.5%	3.5%	2.4%	2.8%	5.2%	
							high (30%)	0.31	0.44	0.66	1.31	2.07	
							low (30%)	0.17	0.24	0.36	0.71	1.11	

* target value from a traceable free PSA standard.

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155		TM151	TM152	TM153	TM154	TM155	
% free PSA all lab mean:												
mean	11.2	10.7	10.4	10.1	9.9		10.2	10.5	9.0	8.7	8.7	
SD	2.4	1.9	1.7	1.3	1.1		2.1	0.9	0.6	0.4	0.3	
%CV	21.7%	17.5%	15.9%	12.6%	10.8%		21.1%	8.2%	6.4%	4.1%	2.9%	
mean+3SD	18.5	16.3	15.4	13.9	13.1		16.6	13.0	10.7	9.7	9.4	
mean-3SD	3.9	5.1	5.5	6.3	6.7		3.7	7.9	7.3	7.6	7.9	
N	45	53	63	39	37		3	4	4	3	3	
mean/target	1.05	1.09	1.21	1.06	1.09	1.10	11.2	10.5	9.2	8.7	8.7	
							0.95	1.07	1.05	0.91	0.95	0.99
% free PSA BC1/BC1 mean:												
mean	12.6	11.9	11.8	11.2	10.9		8.8	8.0	8.8	8.9	9.0	
SD	2.4	1.3	1.0	0.8	0.7		2.0	0.7	1.1	0.6	0.6	
%CV	19.0%	10.8%	8.7%	6.9%	6.0%		22.1%	9.2%	13.0%	6.9%	7.1%	
mean+3SD	19.7	15.8	14.8	13.5	12.9		14.7	10.1	12.2	10.7	10.9	
mean-3SD	5.4	8.0	8.7	8.9	8.9		3.0	5.8	5.3	7.0	7.1	
N	22	29	32	15	14		4	4	4	3	3	
kit median	12.0	12.0	11.7	11.3	11.0		9.8	8.2	8.4	9.0	8.6	
mean/target	1.17	1.21	1.37	1.18	1.20	1.23	0.82	0.81	1.02	0.93	0.99	0.91
% free PSA DP5/DP5 mean:												
mean												
SD												
%CV												
mean+3SD												
mean-3SD												
N												
kit median												
mean/target												
% free PSA BM2/BM1 mean:												
mean	10.5	9.8	9.5	9.8	9.6		10.5	10.0	9.8	9.6	9.5	
SD	1.3	1.1	0.9	0.6	0.6		1.5	1.6	1.4	1.1	1.0	
%CV	12.9%	10.8%	9.1%	6.5%	5.9%		10.3	10.1	9.2	9.4	9.3	
mean+3SD	14.5	12.9	12.1	11.8	11.3							
mean-3SD	6.4	6.6	6.9	7.9	7.9							
N	11	11	16	14	13							
kit median	11.0	9.7	9.5	9.8	9.6							
mean/target	0.98	1.00	1.10	1.04	1.06	1.03						
% free PSA kit average:												
mean												
SD												
all kit median												
% free PSA												
IS target							TM151	TM152	TM153	TM154	TM155	
							10.7%	9.8%	8.6%	9.5%	9.1%	

New York State Proficiency Test May 2006
Summary of Results

	TM151	TM152	TM153	TM154	TM155
Complexed PSA all lab mean:					
mean	2.1	3.3	5.7	9.8	15.9
SD	0.2	0.2	0.4	0.8	1.2
%CV	8.9%	7.3%	6.4%	7.7%	7.6%
mean+3SD	2.7	4.0	6.8	12.1	19.5
mean-3SD	1.6	2.6	4.6	7.5	12.2
N	13	13	13	13	13

	TM151	TM152	TM153	TM154	TM155
% Complexed PSA all lab mean:					
mean	90.2%	89.6%	89.4%	88.9%	86.6%
SD	9.7%	5.1%	7.0%	7.7%	7.9%
%CV	10.7%	5.7%	7.9%	8.7%	9.1%
mean+3SD	119.2%	104.9%	110.5%	112.1%	110.2%
mean-3SD	61.2%	74.4%	68.3%	65.7%	63.0%
N	12	12	12	12	12
all median	88.4%	89.3%	91.1%	90.4%	89.2%

	TM151	TM152	TM153	TM154	TM155
% Complexed PSA BA1/BA1 mean:					
mean	90.4%	90.1%	90.1%	90.2%	86.9%
SD	7.5%	3.6%	6.1%	6.8%	8.3%
%CV	8.3%	4.0%	6.8%	7.6%	9.5%
mean+3SD	112.8%	100.9%	108.3%	110.7%	111.7%
mean-3SD	68.0%	79.3%	71.8%	69.7%	62.0%
N	9	9	9	9	9
kit median	89.3%	89.5%	91.5%	91.3%	90.3%

	TM151	TM152	TM153	TM154	TM155
% Complexed PSA BA1/BC1 mean:					
mean	80.0%	83.9%	81.3%	78.9%	81.2%
N	2	2	2	2	2